Eckert & Ziegler

Eckert & Ziegler reported only modest revenue growth in the first half of 2026 to €149.3m, with adjusted EBIT down 6% to €33.3m. Targets for 2026 were confirmed, but reaching an adjusted EBIT of around €80m could become riskier after delays in gallium-generator deliveries caused by a cyber attack and a weak Isotope Products segment. The share fell through repeatedly tested levels and broke support at €13.30, putting a further decline toward about €12.40 at risk. Long term, the potential remains intact thanks to large actinium-225 capacities and expansion opportunities in China. » More on finanzen.net

Eckert & Ziegler reported unchanged sales of EUR 150m for the first half of 2026, but raised adjusted EBIT to EUR 33m and increased net profit by 5%. Sales of radiopharmaceuticals rose 3% to EUR 70m, while the isotope products segment posted an adjusted EBIT loss down 24%. The company confirmed its full-year guidance of EUR 320m in sales and EUR 80m in EBIT and highlights a strong balance sheet with over EUR 100m cash and only EUR 10m in liabilities. For the second half, management expects improved product-mix growth, a licensing payment and rising industry orders to support the targets. » More on de.investing.com

Eckert & Ziegler continues to benefit from a strong radiopharmaceuticals business and confirms its full-year targets, but suffers from a weak plant business. Revenue in the first six months rose by only 0.4% to €149.3 million. EBIT adjusted for one-off effects fell 6% to €33.3 million, while consolidated net income climbed 4.5% to €22.4 million due to lower currency effects and lower taxes. » More on finanzen.net